Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study.

导出 OA

翻译打印收藏纠错

作者： Daijo,Inaguma ^[1] ; Fumihiko,Koiwa ^[2] ; Masanori,Tokumoto ^[3] ; Masafumi,Fukagawa ^[4] ; Shinji,Yoneda ^[5] ; Hisami,Yasuzawa ^[5] ; Kenji,Asano ^[6] ; Keiko,Hagita ^[6] ; Yosuke,Inagaki ^[6] ; Daisuke,Honda ^[7] ; Tadao,Akizawa ^[8]

作者单位： Department of Internal Medicine, Fujita Health University Bantane Hospital, Aichi, Japan. ^[1] Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan. ^[2] Department of Nephrology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan. ^[3] Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan. ^[4] Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd, Nagoya, Japan. ^[5] Clinical Development Department, Sanwa Kagaku Kenkyusho Co., Ltd, Nagoya, Japan. ^[6] Project Management Department, Sanwa Kagaku Kenkyusho Co., Ltd, Nagoya, Japan. ^[7] Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. ^[8]

关键词 calcimimetics haemodialysis patients parathyroid hormone secondary hyperparathyroidism upacicalcet

DOI 10.1093/ckj/sfad213

PMID 38045997

发布时间 2023-12-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交